NCT03277846View on ClinicalTrials.gov

The Safety and Efficacy of Nexalin Trans-cranial Electrical Stimulation Stimulation for the Treatment of Depression

NACompletedINTERVENTIONAL
Enrollment

101

Participants

Timeline

Start Date

September 1, 2017

Primary Completion Date

May 17, 2018

Study Completion Date

May 17, 2018

Conditions
Depression
Interventions
DEVICE

Nexalin Based Trans-Cranial Electrical Stimulation

The Nexalin device, FDA clearance (501K=K024377, Classification: Stimulator, Cranial Electrotherapy: CFR 882. 5800: U.S. Patent #6904322B2), produces a square waveform that provides trans-cranial electrical stimulation to the brain delivered at a frequency of 77.5 Hz at 0 to 4 mA peak current.

Trial Locations (1)

08502

Carrier Clinic, Belle Mead

All Listed Sponsors
collaborator

Carrier Clinic

OTHER

lead

University of Pennsylvania

OTHER

NCT03277846 - The Safety and Efficacy of Nexalin Trans-cranial Electrical Stimulation Stimulation for the Treatment of Depression | Biotech Hunter | Biotech Hunter